Affiliation:
1. Eli Lilly & Company, Indianapolis, IN 46285, USA
Abstract
Aim: Bioanalytical methods undergo many revisions and modifications throughout drug development to meet the objectives of the study and development program. Results: Validated LC–MS/MS methodology used to quantify abemaciclib and four metabolites in human plasma is described. The method, initially validated to support the first-in-human study, was successfully modified to include additional metabolites as in vitro and in vivo information about the activity and abundance of human metabolites became available. Consistent performance of the method over time was demonstrated by an incurred sample reanalysis passing rate exceeding 95%, across clinical studies. An overview of the numerous methods involved during the development of abemaciclib, including the quantification of drugs evaluated as combination regimens and used as substrates during drug–drug interaction studies, is presented. Conclusion: Robust bioanalytical methods need to be designed with the flexibility required to support the evolving study objectives associated with registration and post-registration trials.
Subject
Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry
Reference24 articles.
1. US FDA. Bioanalytical Method Validation Guidance for Industry (2018). https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf
2. EMA. Guideline on Bioanalytical Method Validation (2011). https://www.ema.europa.eu/en/bioanalytical-method-validation
3. Flow cytometric assays for identity, safety and potency of cellular therapies
4. qPCR and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies
5. Bioanalysis and the oncology revolution
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Therapeutic drug monitoring in breast cancer therapy – LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum;Journal of Pharmaceutical and Biomedical Analysis;2023-02
2. Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis;Bioanalysis;2022-11
3. Development and validation of a reversed‐phase high‐performance liquid chromatography–ultraviolet method for abemaciclib‐related substance detection in bulk drugs;Journal of Separation Science;2022-09-20
4. “A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring”;Journal of Chromatography B;2022-09
5. Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS;Journal of Pharmaceutical Analysis;2022-08